Protalix BioTherapeutics’ (PLX) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Protalix BioTherapeutics (NYSE:PLX – Free Report) in a report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2023 earnings at ($0.03) EPS, FY2023 earnings at $0.16 EPS and […]
More Stories
Iran Offered Better Deal ‘10 Minutes’ After US Canceled Pakistan Meeting, Trump Says
By Jacki Thrapp The Iranian regime offered the United States a “much better” peace deal within 10 minutes of President...
Iran Delegation Leaves Pakistan Without US Talks as Trump Cancels Envoy Visit
By Tom Ozimek Iranian Foreign Minister Abbas Araghchi left Pakistan for Oman on Saturday without meeting U.S. negotiators. Araghchi met...
SBA Refers 562,000 Suspected Fraudulent Loans Worth $22.2 Billion to Treasury
By Naveen Athrappully The Small Business Administration (SBA) has referred 562,000 loans suspected to be fraudulent to the Treasury Department...
US Exports of Crude and Petroleum Products Hit Record Highs
By Jacki Thrapp America’s energy exports have hit record highs as the world navigates the uncertainty surrounding oil and gas...
New Listings Tick Up 3 Percent as Mortgage Rates Continue to Slide
By Rob Sabo New home listings are on the rise across the United States, potentially spurred by hopes of falling...
US, EU Sign Preliminary Partnership Deal on Critical Minerals
By Owen Evans The United States and the European Union signed a memorandum of understanding on April 24 for a...